Presented at the 2009 North American Congress of Clinical Toxicology meeting, San Antonio, TX, September 2009.
Factors Associated With Difficulty Achieving Initial Control With Crotalidae Polyvalent Immune Fab Antivenom in Snakebite Patients
Version of Record online: 16 DEC 2010
© 2010 by the Society for Academic Emergency Medicine
Academic Emergency Medicine
Volume 18, Issue 1, pages 46–52, January 2011
How to Cite
Yin, S., Kokko, J., Lavonas, E., Mlynarchek, S., Bogdan, G. and Schaeffer, T. (2011), Factors Associated With Difficulty Achieving Initial Control With Crotalidae Polyvalent Immune Fab Antivenom in Snakebite Patients. Academic Emergency Medicine, 18: 46–52. doi: 10.1111/j.1553-2712.2010.00958.x
This study was a secondary analysis of data that were originally collected in a study funded by a grant from Fougera (now Nycomed, Zurich, Switzerland). Rocky Mountain Poison and Drug Center also received grant funding to revalidate and reanalyze the data from Protherics (now BTG, West Conshohocken, PA). Rocky Mountain Poison and Drug Center has consultation and call center contracts with Nycomed and BTG. The authors are salaried employees of Rocky Mountain Poison and Drug Center and do not receive any direct funding from Nycomed or BTG.
Supervising Editor: Mark Mycyck, MD.
- Issue online: 10 JAN 2011
- Version of Record online: 16 DEC 2010
- Received April 6, 2010; revisions received June 1 and June 8, 2010; accepted June 9, 2010.
- 3CroFab Prescribing Information. Brentwood, TN: Protherics Inc., 2006..